High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase - PubMed (original) (raw)
High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-activated protein kinase
Masayuki Adachi et al. Hepatology. 2008 Feb.
Abstract
Adiponectin is an adipocyte-derived, antidiabetic, antiatherogenic adipocytokine that is present in serum as 3 isoforms. Decreased plasma adiponectin levels are closely associated with the severity of nonalcoholic fatty liver diseases. This study was designed to elucidate a role of adiponectin and its mediator adenosine monophosphate-activated protein kinase (AMPK) on proliferation of activated hepatic stellate cells (HSCs), the key cells promoting fibrosis. Immortalized human HSC line hTERT and primary rat HSCs were stimulated with platelet-derived growth factor (PDGF) with or without pretreatment with AMPK activator 5-aminoimidazole-4-carboxamide-1-4-ribofuranoside (AICAR), metformin, or high molecular weight (HMW) adiponectin. HMW adiponectin dose-dependently suppressed PDGF-induced HSC proliferation. Adenoviral transduction with dominant-negative AMPK (DN-AMPK) abolished the suppressive effect of adiponectin in HSCs. AICAR, metformin, or transduction of constitutively active AMPK attenuated PDGF-induced [(3)H]thymidine incorporation, which was abolished by either a chemical AMPK inhibitor or transduction of DN-AMPK, consistent with an antiproliferative effect of AMPK. The suppressive effect of AMPK on HSC proliferation is mediated through multiple mechanisms, including (1) an inhibition of the AKT pathway, (2) inhibition of NADPH oxidase-dependent reactive oxygen species (ROS) production via induction of antioxidant enzymes, and (3) an increase in the expression of the cyclin-dependent kinase inhibitors p27(kip1) and p21(cip1).
Conclusion: Adiponectin inhibits HSC proliferation via activation of AMPK. AMPK activation by AICAR or metformin inhibits HSC proliferation via suppression of ROS production and subsequent inhibition of AKT pathway. Thus, adiponectin and AMPK inhibit HSC proliferation and hepatic fibrosis via multiple molecular mechanisms.
Similar articles
- Adenosine monophosphate-activated protein kinase modulates the activated phenotype of hepatic stellate cells.
Caligiuri A, Bertolani C, Guerra CT, Aleffi S, Galastri S, Trappoliere M, Vizzutti F, Gelmini S, Laffi G, Pinzani M, Marra F. Caligiuri A, et al. Hepatology. 2008 Feb;47(2):668-76. doi: 10.1002/hep.21995. Hepatology. 2008. PMID: 18098312 - Adiponectin inhibits insulin-like growth factor-1-induced cell migration by the suppression of extracellular signal-regulated kinase 1/2 activation, but not Akt in vascular smooth muscle cells.
Motobayashi Y, Izawa-Ishizawa Y, Ishizawa K, Orino S, Yamaguchi K, Kawazoe K, Hamano S, Tsuchiya K, Tomita S, Tamaki T. Motobayashi Y, et al. Hypertens Res. 2009 Mar;32(3):188-93. doi: 10.1038/hr.2008.19. Epub 2009 Jan 30. Hypertens Res. 2009. PMID: 19262481 - Activation of AMP-kinase by AICAR induces apoptosis of DU-145 prostate cancer cells through generation of reactive oxygen species and activation of c-Jun N-terminal kinase.
Sauer H, Engel S, Milosevic N, Sharifpanah F, Wartenberg M. Sauer H, et al. Int J Oncol. 2012 Feb;40(2):501-8. doi: 10.3892/ijo.2011.1230. Epub 2011 Oct 13. Int J Oncol. 2012. PMID: 22002081 - [Advances on the anti-inflammatory and protective effect of AMPK activators].
Peng XW, Zhou HH, Dai J, Zhang L. Peng XW, et al. Sheng Li Xue Bao. 2019 Apr 25;71(2):319-326. Sheng Li Xue Bao. 2019. PMID: 31008492 Review. Chinese. - Role of AMPK activation in oxidative cell damage: Implications for alcohol-induced liver disease.
Sid B, Verrax J, Calderon PB. Sid B, et al. Biochem Pharmacol. 2013 Jul 15;86(2):200-9. doi: 10.1016/j.bcp.2013.05.007. Epub 2013 May 17. Biochem Pharmacol. 2013. PMID: 23688501 Review.
Cited by
- Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis.
Savard C, Tartaglione EV, Kuver R, Haigh WG, Farrell GC, Subramanian S, Chait A, Yeh MM, Quinn LS, Ioannou GN. Savard C, et al. Hepatology. 2013 Jan;57(1):81-92. doi: 10.1002/hep.25789. Hepatology. 2013. PMID: 22508243 Free PMC article. - Metformin prevents and reverses inflammation in a non-diabetic mouse model of nonalcoholic steatohepatitis.
Kita Y, Takamura T, Misu H, Ota T, Kurita S, Takeshita Y, Uno M, Matsuzawa-Nagata N, Kato K, Ando H, Fujimura A, Hayashi K, Kimura T, Ni Y, Otoda T, Miyamoto K, Zen Y, Nakanuma Y, Kaneko S. Kita Y, et al. PLoS One. 2012;7(9):e43056. doi: 10.1371/journal.pone.0043056. Epub 2012 Sep 18. PLoS One. 2012. PMID: 23028442 Free PMC article. - AMPK agonist AICAR ameliorates portal hypertension and liver cirrhosis via NO pathway in the BDL rat model.
Hu L, Su L, Dong Z, Wu Y, Lv Y, George J, Wang J. Hu L, et al. J Mol Med (Berl). 2019 Mar;97(3):423-434. doi: 10.1007/s00109-019-01746-4. Epub 2019 Feb 5. J Mol Med (Berl). 2019. PMID: 30721324 Free PMC article. - Moderate alcohol consumption diminishes the development of non-alcoholic fatty liver disease (NAFLD) in ob/ob mice.
Kanuri G, Landmann M, Priebs J, Spruss A, Löscher M, Ziegenhardt D, Röhl C, Degen C, Bergheim I. Kanuri G, et al. Eur J Nutr. 2016 Apr;55(3):1153-64. doi: 10.1007/s00394-015-0929-7. Epub 2015 May 24. Eur J Nutr. 2016. PMID: 26003186 - Epigallocatechin gallate attenuates fibrosis, oxidative stress, and inflammation in non-alcoholic fatty liver disease rat model through TGF/SMAD, PI3 K/Akt/FoxO1, and NF-kappa B pathways.
Xiao J, Ho CT, Liong EC, Nanji AA, Leung TM, Lau TY, Fung ML, Tipoe GL. Xiao J, et al. Eur J Nutr. 2014 Feb;53(1):187-99. doi: 10.1007/s00394-013-0516-8. Epub 2013 Mar 21. Eur J Nutr. 2014. PMID: 23515587
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous